Aruma Labs is partnering with Applied Cannabis Research for an observational study on endometriosis

0
163

Australia’s leading contract research organization focused on medical cannabis treatments

200 women are participating to monitor the safety and effectiveness of medicinal cannabis as a treatment option for refractory chronic pain, a common endometriosis symptom.

SYDNEY, NSW, AUSTRALIA, Jan. 31, 2021 /EINPresswire.com/ – Applied Cannabis Research is pleased to announce that Aruma Labs (Aruma) has participated in Australia’s longest-running observational study of medical cannabis products, the CA Clinics Observational Study (CACOS *) Has. with an emphasis on collecting data from patients with endometriosis.

Endometriosis is a notoriously painful condition that affects more than 11% of Australian women, according to Endometriosis Australia. It is characterized by the presence of endometrial tissue that is normally found in the uterus in other areas of the abdomen. The reduction in quality of life for women with endometriosis has been estimated at A $ 4 billion per year (Ernst & Young (2019): Report on the Cost of Endometriosis in Australia).

200 women will participate in the study to monitor the safety and effectiveness of medicinal cannabis as an additional treatment and treatment option for refractory chronic pain, a common symptom of endometriosis.

KEY HIGHLIGHTS:
-200 Australian women enlisted to participate in Applied Cannabis Research’s observational endometriosis study by CA Clinics
Endometriosis is estimated to affect more than 11% of Australian women, and the diminished quality of life leads to societal costs of $ 4 billion per year
-Aruma will include its cannabis medicines in the study, and Applied Cannabis Research will collect data on its safety and effectiveness, as well as track pain and quality of life (QOL) outcomes in patients prescribed an Aruma product
-The Endometriosis Study is a sub-study of CACOS, an observational study of the health outcomes of 3,000 patients in CA clinics across the country who are prescribed cannabis drugs to treat refractory diseases

Louis Williams, CEO of Aruma commented:
“Research shows that women with endometriosis can often wait up to eight years before being diagnosed. During this time, they can experience debilitating pain, depression, and a reduced quality of life. Through this partnership with Applied Cannabis Research, our goal is to collect patient-reported data to understand whether our unique formulations are suitable as a safe and effective treatment option for the ongoing management of the pain commonly associated with endometriosis. Aruma is committed to finding solutions for patients that make a real and tangible difference in their lives. ”

Dr. John Barlow, Principal Investigator at Applied Cannabis Research, commented, “Endometriosis is a chronic and debilitating condition that affects approximately 11% of women. It is characterized by infertility and chronic pelvic pain, but treatment options remain limited. Medical cannabis is increasingly used to treat refractory pain, but its effectiveness as a therapeutic for endometrial pain is unknown. This observational study will first demonstrate the effectiveness of cannabis in treating endometrial pain, and will show which cannabinoid formulations are most effective. ”

Dr. Mark Hardy, addiction specialist and medical director at CA Clinics, said:
“Chronic pain associated with endometriosis is a complex and debilitating problem for millions of women worldwide. The positive effects of medical cannabis on pain are strong enough for medical cannabis to be considered as a pain management option in addition to current treatments. Cannabinoids are being studied for their effects on the processes of angiogenesis, a key aspect of the pathology of endometriosis, as well as for their anti-inflammatory properties. Evidence-based research on CACOS is critical to better treatment and better health outcomes. “

Dr. Davina Hiley, CA Clinics, added:
“Many women experience distressing endometriosis symptoms. Common treatments such as hormone therapy, analgesia, anti-inflammatory drugs, or even surgery are often persistent and have their own risks and side effects. Therefore, other therapeutic treatment options such as medicinal cannabis must be considered.”

Healthcare professionals and eligible patients 18 and over who would like more information about the endometriosis trial or medical cannabis treatment pathways can contact CA Clinics at 1300 991 477 info@caclinics.com.au

FOR MEDIA INQUIRIES: lisa.mclean@ajdmedia.com.au or by phone on 0412 372 158

AVAILABLE FOR INTERVIEW:

-Louis Williams, CEO of Aruma
-Dr Mark Hardy, CA Clinics Medical Director
-Dr John Barlow, Applied Cannabis Research
-Patient who has been prescribed medical cannabis for endometriosis

ABOUT ARUMA
Aruma is an Australian life science company specializing in the research, development and manufacture of high-quality cannabinoid-based therapeutics for treating unmet medical needs. Aruma aims to inspire hope and provide therapeutic benefits to patients looking for safe and reliable alternative treatment options to traditional therapies.

* ABOUT CACOS (CA Clinics Observational Study)
CACOS aims to collect observational data on safety and health-related outcomes from patients who are prescribed cannabis medicines through CA Clinics. It is an observational study that collects information from patients and their treating physicians about their health-related quality of life and any adverse events associated with treatment with medicinal cannabis. CACOS comprises various products from which data is collected to describe and evaluate medical cannabis for a variety of refractory conditions.

ABOUT APPLIED CANNABIS RESEARCH
Applied Cannabis Research, a division of Southern Cannabis Holdings, is a specialized contract research organization that provides medical expertise and services to medical cannabis companies and other medical cannabis companies. info@appliedcannabisresearch.com.au, (+61) 2 8294 6406 @CannabisApplied

Lisa McLean
AJD Media
+61 412 372 158
lisa.mclean@ajdmedia.com.au
Visit us on social media:
Twitter
LinkedIn

You just read:

News provided by

January 31, 2021, 10:00 PM GMT


ONE Presswire’s priority is source transparency. We don’t allow opaque clients, and our editors try to be careful about weeding out false and misleading content. If, as a user, you see something that we missed, please let us know. Your help is welcome. ONE Presswire, everyone’s internet news Presswire ™, seeks to define some of the limits that are reasonable in the world today. Please see our editorial guidelines for more information.

Submit your press release